In addition, melanoma with N-RAS and B-RAF mutations has been well-recognized as a challenge that brings out more difficulties for the treatment (Brose et al., 2002; Omholt et al., 2003; Thumar et al., 2014). This evidence concerns the gene BRAF and melanoma.